Table 2.
Effectiveness of IPV and mOPV2 campaigns on type 2 seroprevalence.
| Reference Group |
Comparison Group |
|||||
|---|---|---|---|---|---|---|
| Area | Intervention | Vaccines | Seroprevalence (%) (95% CI) | Vaccines (in addition to reference) | Seroprevalence (%) (95% CI) | Intention-to- treat Seroconversion (%) (95% CI) |
| Lahore | Routine only | Routine only | 56 (47, 64) | |||
| Rawalpindi | Routine only | 80 (72, 88) | ||||
| Karachi | IPV SIAs | Routine only | 37 (31, 44) | IPV SIA | 57 (51, 62) | 31 (18, 41) |
| Peshawar | Routine only | 44 (36, 53) | IPV SIA | 68 (63, 73) | 43 (29, 54) | |
| Sukkur | Routine only | 39 (31, 47) | IPV SIA | 87 (82, 92) | 78 (68, 85) | |
| Larkana | Routine only | 50 (38, 62) | IPV SIA | 61 (52, 70) | 22 (-9, 45) | |
| Khyber | – | IPV SIA | 84 (76, 92) | |||
| Mardan & Swabi | Routine only | 63 (51, 76) | IPV SIA | 77 (70, 84) | 38 (3, 61) | |
| Pishin | mOPV2 and IPV SIAs | Routine only | 28 (19, 37) | mOPV2 + IPV SIA | 89 (84, 93) | 84 (77, 89) |
| Killa Abdullah | mOPV2 SIA | 62 (55, 69) | IPV SIA | 64 (57, 70) | 5 (–23, 27) | |
| Quetta | mOPV2 SIA | 72 (65, 79) | mOPV2 + IPV SIA | 83 (78, 88) | 39 (8, 59) | |